NSE · ASTEC · Agro Chemicals
Astec Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹159 Cr with net profit ₹-8 Cr — a -4.9% net margin, versus -17.85% the period before.
Shareholding
As of 2026-06-30
- Promoter71.96%
- Public24.69%
- FII0.01%
- DII3.33%
19,889 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pesticides / Agrochemicals - Indian · ranked #13 of 29 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| UPL Limited | ₹51,406 Cr | 48.46 | 1.48 | 5.54% | 3.71% |
| PI Industries Ltd. | ₹41,782 Cr | 208.63 | 3.72 | 11.76% | 19.67% |
| Sumitomo Chemical India Ltd. | ₹25,042 Cr | 224.98 | 7.39 | 16.02% | 17.86% |
| Sharda Cropchem Ltd. | ₹7,440 Cr | 23.35 | 2.37 | 21.71% | 12.93% |
| Dhanuka Agritech Ltd. | ₹4,589 Cr | 46.93 | 2.73 | 21.17% | 14.59% |
| NACL Industries Limited | ₹4,571 Cr | — | 6.7 | 2.49% | 81.41% |
| Rallis India Ltd. | ₹4,254 Cr | 28.19 | 2.08 | 9.88% | 7.22% |
| Bhagiradha Chemicals & Industries Ltd. | ₹3,463 Cr | 861.45 | 4.96 | 2.6% | 3.39% |
| Bharat Rasayan Ltd. | ₹2,121 Cr | 55.59 | 1.66 | 11.43% | 11.73% |
| Insecticides India Ltd. | ₹1,831 Cr | 156.5 | 1.5 | 0.11% | 6.51% |
| Astec Lifesciences Ltd.(this company) | ₹1,432 Cr | — | 3.67 | -20.72% | -18.06% |
AI analysis
AI-generated · google/gemini-2.5-flashAstec Lifesciences Ltd. is listed with a market capitalization of Rs 1561 Cr. The company reported revenue of Rs 386.93 Cr and an EPS of -68.74. Its book value is Rs 119.36 per share.
Positives
- +Promoter holding is high at 71.97% as of March 31, 2026.
- +No promoter shares are reported as pledged.
Negatives
- −The company has negative earnings per share (EPS) of -68.74.
- −The Return on Equity (ROE) is negative at -44.7%.
- −The Return on Capital Employed (ROCE) is negative at -5.54%.
- −The debt-to-equity ratio is high at 1.74.
- −The company reported a net profit of -7.76 Cr for Mar 2026.
Financial Performance
Astec Lifesciences Ltd. reported a revenue of Rs 386.93 Cr. The company's EPS stands at -68.74. Quarterly results show a revenue of Rs 158.62 Cr for Mar 2026, with a net profit of -7.76 Cr. In the preceding quarter, Dec 2025, revenue was Rs 124.72 Cr and net profit was -15.7 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is -44.7% and Return on Capital Employed (ROCE) is -5.54%. The EPS for the latest period is -68.74. The company has not provided a dividend yield.
Balance Sheet
Astec Lifesciences Ltd. has a debt-to-equity ratio of 1.74. The book value per share is Rs 119.36. The company's market capitalization is Rs 1561 Cr.
Ownership & Pledges
The company has reported no promoter share pledges.
Regulatory & Surveillance
No information regarding surveillance measures has been provided for Astec Lifesciences Ltd. for the reporting period.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.